Member Info for Blownitalready

Tempus has collaborated with several major pharmaceutical companies and healthcare institutions. These include:

* GlaxoSmithKline (GSK): Tempus' AI platform is being used to accelerate drug discovery and development, particularly in oncology.

* AstraZeneca: The company is using Tempus' technology to advance cancer drug development and improve clinical trial design.

* Novartis: Tempus is working with Novartis to identify new drug targets and biomarkers for cancer treatment.

* Memorial Sloan Kettering Cancer Center: This leading cancer center uses Tempus' platform to analyze patient data and develop personalized treatment plans.

* The Mayo Clinic: The Mayo Clinic has partnered with Tempus to leverage AI for precision medicine and improve patient outcomes.

These collaborations demonstrate Tempus' growing reputation as a valuable partner in the field of precision medicine. 💪

Continued -

Potential Clinical Trials: The partnership could lead to clinical trials to evaluate the safety and efficacy of the developed immunotherapies in patients with cancer.

By joining forces, AstraZeneca and Avacta are seeking to address unmet medical needs in oncology and improve patient outcomes. The collaboration represents a significant step forward in the field of cancer immunotherapy.

There have been recent developments at Avacta.

As of October 17, 2024, Avacta has announced the addition of two new preclinical oncology assets, AVA6103 and AVA7100, to its pipeline. These assets are being developed using Avacta's pre|CISION® platform, which aims to optimize drug delivery to tumor environments and reduce systemic toxicity.

This expansion of Avacta's pipeline is a positive sign for the company, as it demonstrates the potential of its technology to address a variety of cancer types.

Would you like to know more about Avacta's recent developments or its technology?

Avacta is a British biotechnology company focused on developing innovative therapies for cancer and other serious diseases. Its core technology, pre|CISION®, is a platform that enables the targeted delivery of drugs to specific cells and tissues in the body.

Here are some key aspects of Avacta's recent developments:

Expansion of Oncology Pipeline:

AVA6103 and AVA7100: These two new preclinical oncology assets are being developed to target specific cancer types. They aim to improve drug delivery to tumor cells and reduce side effects.

Potential for Breakthrough Therapies: Avacta's pre|CISION® platform has the potential to develop novel therapies that address unmet medical needs in oncology.

Other Developments:

Collaboration with AstraZeneca: Avacta has a collaboration with AstraZeneca to develop immuno-oncology therapies using the pre|CISION® platform.

Focus on Innovative Technologies: Avacta continues to invest in research and development to explore new avenues for drug delivery and therapeutic applications.

Overall, Avacta's recent developments demonstrate its commitment to innovation and its potential to make a significant impact in the field of oncology and beyond.

AstraZeneca and Avacta: A Strategic Partnership

AstraZeneca and Avacta have established a strategic partnership focused on the development of novel cancer immunotherapies. This collaboration leverages Avacta's expertise in Affibodies, a proprietary technology platform for the discovery and development of protein-binding molecules, and AstraZeneca's global capabilities in oncology drug development.

Key aspects of the AstraZeneca-Avacta partnership include:

AffiBody Technology: Avacta's AffiBody technology offers a unique approach to targeting cancer cells. Affibodies are small, stable proteins that can be engineered to bind to specific targets with high affinity and specificity.

Immunotherapy Development: The collaboration aims to develop novel cancer immunotherapies that can stimulate the immune system to recognize and attack cancer cells. This could potentially lead to new treatment options for patients with various types of cancer.

Shared Research and Development: AstraZeneca and Avacta are working together on research and development activities, combining their complementary strengths to accelerate the discovery and development of promising drug candidates.

Avacta's innovative approach to cancer therapeutics, particularly their pre|CISION™ platform and AffiBody technology, has garnered significant attention in the pharmaceutical industry.

Given the potential of these technologies to address unmet medical needs, it's highly probable that major pharmaceutical companies are closely monitoring Avacta's progress and exploring potential partnerships or collaborations.

Such partnerships could offer Avacta:

* Financial resources to support further research and development.

* Global reach to bring their therapies to a wider patient population.

* Expertise in drug development, manufacturing, and regulatory affairs.

For big pharma, partnering with Avacta could provide:

* Access to innovative technologies and drug candidates.

* Opportunities to expand their therapeutic portfolios and address new market segments.

* Potential for significant returns on investment.

It's an exciting time for Avacta, and their continued success could lead to significant advancements in cancer treatment.

Coupling Affibodies with imaging agents can provide a powerful tool for visualizing specific targets in the body. This technique, often referred to as AffiBody-based imaging, has several advantages:

* High specificity: Affibodies can be engineered to bind to specific targets with high specificity, allowing for precise visualization of the target.

* Non-invasive: Imaging techniques like PET, SPECT, or MRI can be used to visualize AffiBody-coupled imaging agents without the need for invasive procedures.

* Early detection: AffiBody-based imaging can be used for early detection of diseases by identifying abnormal levels or distributions of target molecules.

* Monitoring treatment response: AffiBody-based imaging can be used to monitor the effectiveness of treatments by visualizing changes in target expression or distribution.

Common imaging modalities used with Affibodies include:

* Positron emission tomography (PET): Affibodies can be coupled with positron-emitting radionuclides to visualize targets using PET scanners.

* Single-photon emission computed tomography (SPECT): Similar to PET, Affibodies can be coupled with single-photon emitting radionuclides for SPECT imaging.

* Magnetic resonance imaging (MRI): Affibodies can be coupled with contrast agents that enhance MRI signals, allowing for visualization of target molecules.

Applications of AffiBody-based imaging include:

* Cancer detection and staging: Identifying and characterizing tumors.

* Monitoring treatment response: Assessing the effectiveness of cancer therapies.

* Neuroimaging: Studying brain function and structure.

* Inflammation imaging: Detecting and monitoring inflammatory processes.

Avacta is using Affibodies in several of their research projects. For example, they are developing Affibodies that can be used to deliver drugs to tumor cells. They are also developing Affibodies that can be used to detect cancer cells.

One of the most promising applications of Affibodies is their potential use in the development of targeted therapies for cancer. Targeted therapies are drugs that are designed to specifically target and kill cancer cells, while leaving healthy cells unharmed. Affibodies can be used to deliver drugs to tumor cells, potentially improving the efficacy of targeted therapies and reducing their side effects.

Avacta is also developing Affibodies that can be used to detect cancer cells. These Affibodies can be used to develop highly sensitive and specific diagnostic tests for cancer. This could help to improve the early detection of cancer and lead to more effective treatments.

In addition to their research on cancer, Avacta is also investigating other potential applications for Affibodies. For example, they are developing Affibodies that can be used to deliver drugs to the brain. This could have potential applications in the treatment of neurological disorders such as Alzheimer's disease and Parkinson's disease.

Overall, Affibodies are a promising technology with a wide range of potential applications. Avacta is at the forefront of research in this area, and their work could have a significant impact on the development of new therapies and diagnostic tools.

🤯🤯🤯

I really hope this is happening 🙏

Affibodies are indeed a fascinating technology. They are small, synthetic proteins that can be engineered to bind to specific targets with high affinity and specificity. This unique property makes them highly versatile and has potential applications in various fields, including:

* Drug delivery: Affibodies can be used to deliver drugs to specific cells or tissues, potentially improving the efficacy and reducing the side effects of treatments.

* Diagnostics: Affibodies can be used to develop highly sensitive and specific diagnostic tests for various diseases.

* Research: Affibodies can be used as research tools to study protein-protein interactions and other biological processes.

One of the key advantages of Affibodies is their small size. This makes them less likely to be immunogenic, which means they are less likely to trigger an immune response in the body. Additionally, their modular design allows for easy customization, enabling researchers to create Affibodies with specific properties to suit their needs.

Avacta's expertise in Affibodies is a significant strength. Their platform technology has the potential to drive the development of innovative new therapies and diagnostic tools.

Avacta is a biotechnology company focused on developing innovative therapies for cancer. They have a pipeline of products in various stages of development, including:

1. AVA6000: This is a potential first-in-class targeted therapy for solid tumors. It is designed to inhibit the interaction between tumor cells and the extracellular matrix, which can lead to tumor growth and metastasis. AVA6000 is currently in Phase 1 clinical trials.

2. AVA0505: This is a potential first-in-class targeted therapy for multiple myeloma. It is designed to inhibit the interaction between tumor cells and the bone marrow microenvironment, which can lead to tumor growth and progression. AVA0505 is currently in preclinical development.

3. AVA0101: This is a potential first-in-class targeted therapy for prostate cancer. It is designed to inhibit the interaction between tumor cells and the bone marrow microenvironment, which can lead to tumor growth and progression. AVA0101 is currently in preclinical development.

4. AVA0303: This is a potential first-in-class targeted therapy for breast cancer. It is designed to inhibit the interaction between tumor cells and the extracellular matrix, which can lead to tumor growth and metastasis. AVA0303 is currently in preclinical development.

5. AVA0202: This is a potential first-in-class targeted therapy for pancreatic cancer. It is designed to inhibit the interaction between tumor cells and the extracellular matrix, which can lead to tumor growth and metastasis. AVA0202 is currently in preclinical development.

In addition to these pipeline products, Avacta is also developing a platform technology called Affibodies. Affibodies are small, synthetic proteins that can be engineered to bind to specific targets with high affinity and specificity. This technology has potential applications in a variety of areas, including drug delivery, diagnostics, and research.

Avacta has a strong R&D team and a number of collaborations with leading academic institutions and pharmaceutical companies. The company is committed to developing innovative therapies that can improve the lives of patients with cancer.

Using the Gemini app - The exact date the Avacta and Elicio partnership was announced is September 10, 2024.

the partnership between Avacta and Elicio Therapeutics appears to be a promising collaboration.

Here are some key reasons why:

* Complementary Technologies: Avacta's Affimer® platform and Elicio's INTEGRATE™ platform offer complementary capabilities, allowing them to develop novel cancer immunotherapies with enhanced efficacy.

* Strong Scientific Foundation: Both companies have strong scientific teams and a solid track record in developing innovative therapeutics.

* Shared Vision: Avacta and Elicio share a common vision of developing transformative cancer treatments that address unmet medical needs.

* Synergy: The partnership has the potential to create synergies that could accelerate drug development and reduce costs.

While it's important to note that the success of any partnership depends on various factors, including the execution of the collaboration and the clinical outcomes of the developed therapies, the partnership between Avacta and Elicio has the potential to be a significant force in the field of cancer immunotherapy.

I just used the *Gemini* app and asked about Avacta and it gave up the information I gave.

INTEGRATE™ is a proprietary platform developed by Elicio Therapeutics, a clinical-stage biotechnology company focused on developing novel cancer immunotherapies.

This platform enables the creation of multi-antigen T cell receptor (TCR) therapies. These therapies are designed to target multiple neoantigens simultaneously, which are unique proteins expressed by cancer cells.

By targeting multiple antigens, INTEGRATE™ therapies aim to:

* Increase the effectiveness of cancer immunotherapy: Traditional immunotherapies often focus on a single target, which can lead to tumor escape. By targeting multiple antigens, INTEGRATE™ therapies can potentially overcome this limitation.

* Reduce the risk of tumor relapse: Cancer cells can develop resistance to therapies over time. By targeting multiple antigens, INTEGRATE™ therapies can make it more difficult for tumors to evade treatment.

Elicio Therapeutics is currently developing INTEGRATE™ therapies for various types of cancer. The company believes that this platform has the potential to revolutionize the treatment of cancer by providing patients with more effective and durable therapies.

👍💪

Avacta Group plc and Elicio Therapeutics, Inc. are two biotechnology companies that have entered into a partnership to develop novel cancer immunotherapies.

Avacta is a British life sciences company that develops innovative, targeted cancer treatments and powerful diagnostics. The company's two key platforms are pre|CISION™ and Affimer®. pre|CISION™ is a peptide drug conjugate platform that leverages the tumor-specific expression of FAP. Affimer® is a proprietary platform for generating highly specific, high-affinity proteins.

Elicio Therapeutics is a clinical-stage biotechnology company focused on developing novel cancer immunotherapies. The company's proprietary platform, INTEGRATE™, enables the creation of multi-antigen T cell receptor (TCR) therapies that target multiple neoantigens simultaneously.

The partnership between Avacta and Elicio aims to leverage their complementary technologies to develop novel cancer immunotherapies. Avacta's Affimer® technology will be used to identify and isolate tumor-associated antigens, while Elicio's INTEGRATE™ platform will be used to create multi-antigen TCR therapies that target these antigens.

*Apparently this partnership was in September....I never knew that 🤔

Can't believe I've been able to top up 10 times since February... what's not to like 👍

The future couldn't be clearer.....long term this company is going to be put front and centre with the big boys.

World’s first mouse model with fully functional human immune system developed

This new approach may offer a viable alternative to the use of non-human primates in immunological and microbiological research.....

( More in the link )

https://interestingengineering.com/science/first-mouse-model-human-immune-system

Https://www.fda.gov/news-events/press-announcements/fda-roundup-may-31-2024

On Wednesday, the FDA notified selected participants of their acceptance into the Support for Clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program. The pilot, announced in September 2023, is being conducted by the FDA’s Center for Biologics Evaluation and Research and Center for Drug Evaluation and Research to help further accelerate the development of novel drug and biological products that are intended to address an unmet medical need as a treatment for a rare disease. Selected participants will be able to interact with the FDA through rapid, ad-hoc communication mechanisms to provide a mechanism for addressing product-specific development issues, including but not limited to clinical study design, choice of control group, fine-tuning the choice of patient population, leveraging nonclinical information, or product characterization. These enhanced communications are intended to augment currently available formal meeting procedures between the FDA and sponsors relating to the development and review of drug or biological products.

GSK getting their finances topped up for drug pipeline 🤔

https://www.dailymail.co.uk/money/markets/article-12972855/GSK-sells-978m-stake-Haleon-drugmaker-cuts-holding-4-2.html

Https://www.japantimes.co.jp/commentary/2023/12/29/world/targeted-cancer-drugs/

"Targeted cancer drugs finally live up to the hype"

Read on.....

RNS !

From RBS.

"The continuing success of AVA6000 in the Phase 1a clinical study is important not only for the potential to improve outcomes for patients with cancers suitable for treatment with doxorubicin, but also as a validation of the pre|CISIONTM platform more widely. The Company aims to complete the AVA6000 three-weekly dose escalation safety study and to provide a detailed data read-out during Q4 2023."

So anytime !